Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2021 10/14/2021 10/15/2021 10/18/2021 10/19/2021 Date
21.45(c) 21.84(c) 21.82(c) 21.31(c) 21.5 Last
1 138 242 1 247 026 3 196 875 1 438 039 755 367 Volume
+0.23% +1.82% -0.09% -2.34% +0.89% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 392 M - -
Net income 2021 210 M - -
Net cash position 2021 989 M - -
P/E ratio 2021 33,7x
Yield 2021 -
Sales 2022 1 649 M - -
Net income 2022 265 M - -
Net cash position 2022 1 216 M - -
P/E ratio 2022 25,1x
Yield 2022 -
Capitalization 6 714 M 6 714 M -
EV / Sales 2021 4,11x
EV / Sales 2022 3,33x
Nbr of Employees 773
Free-Float 98,0%
More Financials
Company
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from... 
More about the company
Ratings of Exelixis, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EXELIXIS, INC.
04:07pEXELIXIS : to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
BU
10/18INSIDER SELL : Exelixis
MT
10/15EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
AQ
10/14EXELIXIS : Storm Therapeutics Sign Collaboration, License Deal to Discover Cancer Treatmen..
MT
10/14EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
BU
10/14EXELIXIS : and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement..
BU
10/14Exelixis, Inc. Exercises Exclusive Option Under the Companies’ July 2019 Agreement
CI
10/07EXELIXIS : Jefferies Starts Exelixis at Buy with $28 Price Target
MT
09/20EXELIXIS : Reports Final Results From Phase 3 Trial of Thyroid Cancer Treatment
MT
09/20EXELIXIS : Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in ..
BU
09/20Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in..
CI
09/20EXELIXIS : Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previ..
AQ
09/20EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
AQ
09/20EXELIXIS : Truist Securities Adjusts Price Target on Exelixis to $36 From $37, Maintains B..
MT
09/18EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
BU
More news
News in other languages on EXELIXIS, INC.
10/14Exelixis et Storm Therapeutics signent un accord de collaboration et de licence pour dé..
09/20Exelixis annonce les résultats finaux de l'essai de phase 3 du traitement du cancer de ..
09/17Exelixis obtient l'approbation de la FDA pour Cabometyx dans le traitement du cancer de..
09/16Exelixis déclare que de nouvelles données exploratoires issues d'un essai de phase avan..
09/07Décès du médecin-chef d'Exelixis
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 21,31 $
Average target price 31,46 $
Spread / Average Target 47,6%
EPS Revisions
Managers and Directors
Michael M. Morrissey President, Chief Executive Officer & Director
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Dana T. Aftab Executive Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.6.18%6 714
GILEAD SCIENCES, INC.13.11%82 626
WUXI APPTEC CO., LTD.29.16%65 873
BIONTECH SE220.28%63 059
REGENERON PHARMACEUTICALS12.50%56 504
VERTEX PHARMACEUTICALS-23.50%46 905